½ÃÀ庸°í¼­
»óǰÄÚµå
1490109

±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå : ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Acute Repetitive Seizures Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀåÀº 2024³â 31¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 12.6% ¼ºÀåÇÏ¿© 2031³â¿¡´Â 71¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2023³â 2024³â ½ÃÀå ±Ô¸ð 31¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ 2024-2031³â CAGR: 12.60% 2031³â °¡Ä¡ ¿¹Ãø 71¾ï 2,000¸¸ ´Þ·¯
±×¸². ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Acute Repetitive Seizures Market-IMG1

±Þ¼º ¹Ýº¹¼º ¹ßÀÛ(ARS)Àº 24½Ã°£ ³»¿¡ 2ȸ ÀÌ»óÀÇ ºñÀ¯¹ß¼º ¹ßÀÛÀÌ ¹ß»ýÇϸç, ¹ßÀÛ°ú ¹ßÀÛ »çÀÌ¿¡ ÀǽÄÀÌ È¸º¹µÇÁö ¾Ê´Â °ÍÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ±Þ¼º ¹Ýº¹¼º ¹ßÀÛÀº °£Áú ȯÀÚÀÇ Áúº´ ºÎ´ã¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ARS ȯÀÚ°¡ Áõ°¡ÇÏ´Â ¿äÀÎÀ¸·Î´Â ¹ßÀÛ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡, ³úÁ¹Áß, ³ú¼Õ»ó, ½Å°æ °¨¿°À¸·Î ÀÎÇÑ °£Áú À¯º´·üÀÇ Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Â÷¼¼´ë Ç×°æ·ÃÁ¦ ¹× º´¿ø ³» ÀÀ±Þ Ä¡·á Àü¿ë ÇÁ·ÎÅäÄݰú °°Àº ARS Ä¡·á ¿É¼ÇÀÇ ¹ßÀüÀº ȯÀÚ¸¦ µ½°í °¡±î¿î Àå·¡¿¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è °£Áú À¯º´·üÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è °£Áú ȯÀÚ ¼ö´Â 5,000¸¸ ¸íÀ¸·Î Ãß»êµË´Ï´Ù. ¶ÇÇÑ °£Áú ¹ßÀÛÀ¸·Î À̾îÁö´Â ½Å°æ Àå¾Ö, ³úÁ¹Áß ¹× ³ú ¼Õ»ó¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ±×·¯³ª Àú¼Òµæ Áö¿ªÀÇ ³ôÀº ÀÀ±Þ ÀÇ·á ºñ¿ë°ú ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àú·ÅÇÑ Á¦³×¸¯ Ç×°æ·ÃÁ¦ÀÇ °³¹ßÀº ½ÃÀå ¼ºÀå ±âȸ¸¦ Á¦°øÇϸç, ARSÀÇ Àû½Ã ½Äº° ¹× Ä¡·á¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇÑ ÀÌ´Ï¼ÅÆ¼ºê´Â »ç¸Á·ü°ú Àå¾ÖÀ²À» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2024-2031³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAG%)À» ÅëÇØ Àü ¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÕ´Ï´Ù.
  • ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀåÀº ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Àμö¿Í Á¦ÈÞ ½Ã³ª¸®¿À
  • ÀÚ±Ý Á¶´Þ°ú ÅõÀÚ
  • PEST ºÐ¼®
  • Porters ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê
  • COVID-19ÀÇ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ¼¼°è ½ÃÀå, ¾à¹° À¯Çüº°, 2019-2031³â

  • º¥Á¶µð¾ÆÁ¦ÇÉ
  • Ç×°£ÁúÁ¦
  • ¹Ù¸£ºñÆ®¸£»ê
  • ±âŸ(Èı⠰³¹ß Á¦Ç° µî)

Á¦6Àå ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ¼¼°è ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2031³â

  • °æ±¸
  • ÁÖ»ç
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå, À¯Åë ä³Îº°, 2019-2031³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ ±Þ¼º ¹Ýº¹¼º ¹ßÀÛ ½ÃÀå, Áö¿ªº°, 2019-2031³â

Á¦9Àå °æÀï »óȲ

  • ±â¾÷ °³¿ä
    • Neurelis, Inc.
    • Bausch Health Companies Inc.
    • Alexza Pharmaceuticals, Inc.
    • VERITON PHARMA
    • UCB SA
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Sanofi
    • GSK plc
    • Eisai Co., Ltd.
    • H. Lundbeck A/S
    • Cognizance Biomarkers, LLC

Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È

  • Wheel of Fortune
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦11Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
ksm 24.06.13

Global acute repetitive seizures market is estimated to be valued at USD 3.10 Bn in 2024 and is expected to reach USD 7.12 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 3.10 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 12.60% 2031 Value Projection: US$ 7.12 Bn
Figure. Acute Repetitive Seizures Market Share (%), By Region 2024
Acute Repetitive Seizures Market - IMG1

Acute repetitive seizures (ARS) are characterized by two or more unprovoked seizures occurring within a 24-hour period without restoration of consciousness between the seizures. Acute repetitive seizures contributes significantly to the disease burden among epileptic patients. Factors contributing to increase in ARS cases globally includes growing geriatric population prone to seizures and increasing prevalence of epilepsies arising from strokes, brain injuries, and neuroinfectious. However, advancements in ARS treatment options such as newer generation anticonvulsants and dedicated emergency treatment protocols in hospitals are expected to aid patients and drive the market growth in the near future.

Market Dynamics:

Global acute repetitive seizures market growth is p driven by increasing incidence of epilepsy worldwide. It is estimated that 50 million people suffer from epilepsy globally. Furthermore, rising geriatric population susceptible to neurological disorders, strokes, and brain injuries leading to seizures boosts demand for acute repetitive seizures treatment over the forecast period. However, high costs of emergency care and unmet medical needs in low-income regions can hamper the market growth. Development of inexpensive generic anticonvulsants provides opportunities for the market growth. Initiatives aimed at raising awareness about timely identification and treatment of ARS can reduce mortality and disability rates.

Key Features of the Study:

  • This report provides an in-depth analysis of the global acute repetitive seizures market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global acute repetitive seizures market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this includes Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global acute repetitive seizures market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute repetitive seizures market.

Detailed Segmentation-

  • By Drug Type:
    • Benzodiazepines
    • Antiepileptic drugs
    • Barbiturates
    • Others (Late Phase Drugs, etc.)
  • By Route of Administration:
    • Oral
    • Injectable
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Neurelis, Inc.
    • Bausch Health Companies Inc.
    • Alexza Pharmaceuticals, Inc.
    • VERITON PHARMA
    • UCB S.A.
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc.
    • Sanofi
    • GSK plc
    • Eisai Co., Ltd.
    • Lundbeck A/S
    • Cognizance Biomarkers, LLC

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Acute Repetitive Seizures Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global Acute Repetitive Seizures Market, By Drug Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Benzodiazepines
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Antiepileptic drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Barbiturates
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others (Late Phase Drugs, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Acute Repetitive Seizures Market, By Route of Administration, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Injectable
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Acute Repetitive Seizures Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Acute Repetitive Seizures Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2020-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
      • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
      • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
      • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
      • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Neurelis, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bausch Health Companies Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Alexza Pharmaceuticals, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • VERITON PHARMA
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • UCB S.A.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Takeda Pharmaceutical Company Limited
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • GSK plc
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Eisai Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • H. Lundbeck A/S
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Cognizance Biomarkers, LLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦